NO993912L - FremgangsmÕte for fremstilling av eprosartan - Google Patents

FremgangsmÕte for fremstilling av eprosartan

Info

Publication number
NO993912L
NO993912L NO993912A NO993912A NO993912L NO 993912 L NO993912 L NO 993912L NO 993912 A NO993912 A NO 993912A NO 993912 A NO993912 A NO 993912A NO 993912 L NO993912 L NO 993912L
Authority
NO
Norway
Prior art keywords
eprosartan
preparation
Prior art date
Application number
NO993912A
Other languages
English (en)
Other versions
NO317761B1 (no
NO993912D0 (no
Inventor
Richard T Matsuoka
Peng Liu
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of NO993912L publication Critical patent/NO993912L/no
Publication of NO993912D0 publication Critical patent/NO993912D0/no
Publication of NO317761B1 publication Critical patent/NO317761B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO993912A 1997-02-14 1999-08-13 Fremgangsmåte for fremstilling av eprosartan NO317761B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3819697P 1997-02-14 1997-02-14
PCT/US1998/002411 WO1998035962A1 (en) 1997-02-14 1998-02-13 Process for preparing eprosartan

Publications (3)

Publication Number Publication Date
NO993912L true NO993912L (no) 1999-08-13
NO993912D0 NO993912D0 (no) 1999-08-13
NO317761B1 NO317761B1 (no) 2004-12-13

Family

ID=21898590

Family Applications (1)

Application Number Title Priority Date Filing Date
NO993912A NO317761B1 (no) 1997-02-14 1999-08-13 Fremgangsmåte for fremstilling av eprosartan

Country Status (41)

Country Link
US (2) US6294675B1 (no)
EP (1) EP0973769B1 (no)
JP (1) JP4227671B2 (no)
KR (1) KR100551667B1 (no)
CN (1) CN1093128C (no)
AP (1) AP1202A (no)
AR (1) AR011126A1 (no)
AT (1) ATE274511T1 (no)
AU (1) AU730162B2 (no)
BG (1) BG63970B1 (no)
BR (1) BRPI9808642B8 (no)
CA (1) CA2281471C (no)
CO (1) CO4950549A1 (no)
CY (1) CY2551B1 (no)
CZ (1) CZ296543B6 (no)
DE (1) DE69825880T2 (no)
DK (1) DK0973769T3 (no)
DZ (1) DZ2418A1 (no)
EA (1) EA001761B1 (no)
EG (1) EG23780A (no)
ES (1) ES2224358T3 (no)
HK (1) HK1026206A1 (no)
HU (1) HU228098B1 (no)
ID (1) ID23155A (no)
IL (4) IL143784A (no)
IN (1) IN188000B (no)
MA (1) MA24472A1 (no)
MY (1) MY120024A (no)
NO (1) NO317761B1 (no)
NZ (1) NZ337182A (no)
OA (1) OA11086A (no)
PE (1) PE59799A1 (no)
PL (1) PL192837B1 (no)
PT (1) PT973769E (no)
SA (1) SA98190146B1 (no)
SI (1) SI0973769T1 (no)
SK (1) SK285125B6 (no)
TR (1) TR199901935T2 (no)
UA (1) UA57060C2 (no)
WO (1) WO1998035962A1 (no)
ZA (1) ZA981208B (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR011126A1 (es) * 1997-02-14 2000-08-02 Smithkline Beecham Corp Procedimiento para preparar eprosartano y compuestos intermediarios.
US6630498B2 (en) * 1997-08-06 2003-10-07 Smithkline Beecham Corporation Eprosartan arginyl charge-neutralization-complex and a process for its preparation and formulation
NZ509378A (en) * 1998-07-20 2003-04-29 Smithkline Beecham Corp Amorphous ammonium salts of eprosartan and pharmaceuticals thereof, useful for blocking angiotensin II receptors and useful for treating hypertension, congestive heart disease and renal failure
US20060099230A1 (en) * 2004-11-10 2006-05-11 Chin-Chih Chiang Novel formulations of eprosartan with enhanced bioavailability
US20100137613A1 (en) * 2006-12-27 2010-06-03 Hetero Drugs Limited Process for eprosartan
NZ584845A (en) * 2007-10-22 2011-09-30 Orchid Res Lab Ltd Histone deacetylase inhibitors
CN101215284B (zh) * 2007-12-31 2010-10-13 浙江华海药业股份有限公司 一种改进的依普罗沙坦的制备方法
WO2011004384A2 (en) 2009-06-05 2011-01-13 Glochem Industries Limited Process for the preparation of eprosartan
CN102584709B (zh) * 2011-12-19 2016-08-17 浙江华海药业股份有限公司 一种改进的依普罗沙坦中间体芳基咪唑醛的制备工艺
CN103288742A (zh) * 2013-06-04 2013-09-11 四川百利药业有限责任公司 一种高纯度英加韦林原料的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE250587T1 (de) * 1989-06-14 2003-10-15 Smithkline Beecham Corp Imidazoalkensäure
US5418250A (en) * 1989-06-14 1995-05-23 Smithkline Beecham Corporation Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
US5185351A (en) * 1989-06-14 1993-02-09 Smithkline Beecham Corporation Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
NZ239161A (en) * 1990-07-31 1994-01-26 Smithkline Beecham Corp Substituted [1h-imidazol-5-yl] alkanoic acid derivatives; medicaments,
AU9137791A (en) * 1990-12-14 1992-07-08 Smithkline Beecham Corporation Imidazolyl-alkenoic acids
AR011126A1 (es) * 1997-02-14 2000-08-02 Smithkline Beecham Corp Procedimiento para preparar eprosartano y compuestos intermediarios.

Also Published As

Publication number Publication date
IL143785A0 (en) 2002-04-21
EG23780A (en) 2007-08-13
ATE274511T1 (de) 2004-09-15
BR9808642A (pt) 2000-05-23
CA2281471A1 (en) 1998-08-20
TR199901935T2 (xx) 1999-12-21
PL335074A1 (en) 2000-04-10
CO4950549A1 (es) 2000-09-01
OA11086A (en) 2003-03-13
JP4227671B2 (ja) 2009-02-18
AP9901619A0 (en) 1999-09-30
CA2281471C (en) 2007-04-24
SK108699A3 (en) 2000-05-16
US20020028951A1 (en) 2002-03-07
NZ337182A (en) 2001-04-27
SK285125B6 (sk) 2006-06-01
CZ285199A3 (cs) 2000-02-16
US6294675B1 (en) 2001-09-25
HUP0001813A3 (en) 2001-07-30
BG103649A (en) 2000-06-30
EP0973769A4 (en) 2001-01-24
NO317761B1 (no) 2004-12-13
DK0973769T3 (da) 2004-12-13
CZ296543B6 (cs) 2006-04-12
HK1026206A1 (en) 2000-12-08
SA98190146B1 (ar) 2006-08-20
BRPI9808642B8 (pt) 2021-05-25
IL143783A0 (en) 2002-04-21
EA001761B1 (ru) 2001-08-27
EA199900741A1 (ru) 2000-02-28
DE69825880D1 (de) 2004-09-30
HUP0001813A2 (hu) 2001-06-28
ES2224358T3 (es) 2005-03-01
BG63970B1 (bg) 2003-08-29
ZA981208B (en) 1998-11-12
IL143783A (en) 2005-05-17
CN1247538A (zh) 2000-03-15
IL131310A (en) 2003-02-12
IL143785A (en) 2004-12-15
JP2001511808A (ja) 2001-08-14
IL143784A (en) 2005-05-17
HU228098B1 (en) 2012-10-29
AP1202A (en) 2003-09-02
EP0973769B1 (en) 2004-08-25
MY120024A (en) 2005-08-30
PT973769E (pt) 2004-11-30
IN188000B (no) 2002-08-03
PE59799A1 (es) 1999-08-06
DZ2418A1 (fr) 2003-06-26
KR100551667B1 (ko) 2006-02-13
CN1093128C (zh) 2002-10-23
MA24472A1 (fr) 1998-10-01
IL143784A0 (en) 2002-04-21
EP0973769A1 (en) 2000-01-26
CY2551B1 (en) 2008-07-02
ID23155A (id) 2000-03-23
AR011126A1 (es) 2000-08-02
KR20000071008A (ko) 2000-11-25
PL192837B1 (pl) 2006-12-29
BR9808642B1 (pt) 2013-11-26
DE69825880T2 (de) 2005-09-08
AU730162B2 (en) 2001-03-01
IL131310A0 (en) 2001-01-28
WO1998035962A1 (en) 1998-08-20
SI0973769T1 (en) 2004-12-31
UA57060C2 (uk) 2003-06-16
US6458963B1 (en) 2002-10-01
AU6273298A (en) 1998-09-08
NO993912D0 (no) 1999-08-13

Similar Documents

Publication Publication Date Title
NO20011936D0 (no) Fremgangsmåte for fremstilling av Citalopram
NO20015017L (no) Fremgangsmate for fremstilling av citalopram
NO20010318L (no) Fremgangsmåte for fremstilling av Citalopram
NO20002443L (no) FremgangsmÕte for fremstilling av derivater av taxoidklassen
NO20010319L (no) Fremgangsmate for fremstilling av Citalopram
NO20000189L (no) Fremgangsmõte for fremstilling av heparin
NO993912L (no) FremgangsmÕte for fremstilling av eprosartan
NO20023937D0 (no) Fremgangsmåte for fremstilling av substituert tiazolidindion
NO20003454D0 (no) FremgangsmÕte for fremstilling av (-)cis-3-hydroksy-1-metyl-4-
NO993913D0 (no) Fremgangsmåte for fremstilling av eprosartan
NO20000933D0 (no) Fremgangsmåte for fremstilling av polymer
NO20001777L (no) Fremgangsmate for fremstilling av substituerte 4-fenyl-4-cyanocykloheksankarboksylsyrer
NO996432L (no) Fremgangsmåte for fremstilling av 4-substituert-1H-indol-3- glykosamider
NO995388D0 (no) Fremgangsmåte for fremstilling av formylfosfonsyre
NO20013995D0 (no) Fremgangsmate for fremstilling av L-sorbose
NO980316D0 (no) Fremgangsmåte for fremstilling av polymerisater av N-vinylkarprolaktam
NO20003077D0 (no) FremgangsmÕte for fremstilling av klorbenzooksazolen
NO20001793L (no) FremgangsmÕte ved fremstilling av azacykloalkylalkanoylpseudotetrapeptider
NO991679L (no) Fremgangsmaate for fremstilling av fenoksyfenylsulfonylhalider
NO20012811D0 (no) Fremgangsmåte for fremstilling av p-klorfenyl-propanol- derivat
NO20020328D0 (no) Fremgangsmåte for fremstilling av 4-cyano-2-aminometyltiazol
NO994557D0 (no) Fremgangsmaate for fremstilling av arylaminotriazolopyridiner
NO20013044L (no) Fremgangsmåte for fremstilling av NG-substituerte deaza- adenosinderivater
NO20005743L (no) Fremgangsmåte til fremstilling av 4,5-epoksymorfinan-6- glukuronider
NO20020327D0 (no) Fremgangsmåte for fremstilling av 2-aminometyl-4-cyano-tiazol

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: GLAXOSMITHKLINE LLC, US

MK1K Patent expired